1086 NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumors
Damon J. Hamel(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Werner Rubas(University of California, San Francisco), Olga Zemska(Nektar Therapeutics (United States)), Saul Kivimäe(Nektar Therapeutics (United States)), Arkopal Choudhury(Nektar Therapeutics (United States)), Marlene Hennessy(Nektar Therapeutics (United States)), Sarah Ingersoll(Amgen (United States)), Christie Fanton(Nektar Therapeutics (United States)), David Doherty(Loyola University Chicago), Guifen Xu(Sutro Biopharma (United States)), Danni Yu(National Heart Lung and Blood Institute), Takahiro Miyazaki(Kyushu University), Thomas Ming Swi Chang(McGill University), Phi Quatch(Nektar Therapeutics (United States)), Rhoneil Pena(Nektar Therapeutics (United States)), Brian R. Vuillemenot(Nektar Therapeutics (United States))
Cited by 0
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
Cell encapsulation: Promise and progress
|Nature Medicine|2003|592
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403
History, challenges and perspectives of cell microencapsulation
|Trends in biotechnology|2003|346